Louise Warnich | Drögemöller Lab

Latest

Fine-mapping of antipsychotic response genome-wide association studies reveals novel regulatory mechanisms
The identification of novel genetic variants associated with antipsychotic treatment response outcomes in first-episode schizophrenia patients
CYP2B6*6 and CYP2B6*18 predict long-term efavirenz exposure measured in hair samples in HIV-positive South African women
Evaluation of predictive CYP2C19 genotyping assays relative to measured phenotype in a South African cohort
Considerations for rare variants in drug metabolism genes and the clinical implications
Patterns of variation influencing antipsychotic treatment outcomes in South African first-episode schizophrenia patients
Next-generation sequencing of pharmacogenes: a critical analysis focusing on schizophrenia treatment
Characterization of the genetic variation present in CYP3A4 in three South African populations
Introduction of the AmpliChip CYP450 test to a South African cohort: a platform comparative prospective cohort study
Association of MB-COMT polymorphisms with schizophrenia-susceptibility and symptom severity in an African cohort
Whole-genome resequencing in pharmacogenomics: moving away from past disparities to globally representative applications
Psychiatric genetics in South Africa: cutting a rough diamond
Pharmacogenomic research in South Africa: Lessons learned and future opportunities in the rainbow nation
Characterization of the genetic profile of CYP2C19 in two South African populations
Elucidation of CYP2D6 genetic diversity in a unique African population: implications for the future application of pharmacogenetics in the Xhosa population